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Abstract
Cognitive deficits in schizophrenia are a major source of dysfunction for which more effective 
treatments are needed. The vasopressin-deficient Brattleboro (BRAT) rat has been shown to have 
several natural schizophrenia-like deficits, including impairments in prepulse inhibition and 
memory. We investigated BRAT rats and their parental strain, Long Evans (LE) rats, in a social 
discrimination paradigm, which is an ethologically-relevant animal test of cognitive deficits of 
schizophrenia based upon the natural preference of animals to investigate conspecifics. We also 
investigated the effects of the atypical antipsychotic, clozapine and the putative antipsychotic, 
PD149163, a brain-penetrating neurotensin-1 analogue, on social discrimination in these rats. 
Adult rats were administered saline or one of three doses of clozapine (0.1, 1.0 or 10 mg/kg) or 
PD149163 (0.1, 0.3 or 1.0 mg/kg), subcutaneously. Following drug administration, adult rats were 
exposed to a juvenile rat for a 4-minute learning period. Animals were then housed individually 
for 30 minutes and then simultaneously exposed to the previously presented juvenile and a new 
juvenile for 4 minutes. Saline-treated LE rats, but not BRAT rats, exhibited intact social 
discrimination as evidenced by greater time spent exploring the new juvenile. The highest dose of 
clozapine and the two highest doses of PD149163 restored social discrimination in BRAT rats. 
These results provide further support for the utility of the BRAT rat as a genetic animal model 
relevant to schizophrenia and drug discovery. The potential of neurotensin agonists as putative 
treatments for cognitive deficits of schizophrenia was also supported.
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INTRODUCTION
Cognitive deficits of schizophrenia are a core feature of schizophrenia and several other 
neuropsychiatric disorders. Cognitive deficits of schizophrenia are among the first detectable 
symptoms and are consistent from the first episode throughout middle age (Hagan and 
Jones, 2005). Evidence suggests that cognitive deficits have strong adverse effects on the 
functional status of schizophrenia patients (Green et al, 2000; 2004). The Measure and 
Treatment Research to Improve Cognition in Schizophrenia (MATRICS) committee 
identified seven distinct and replicable domains of cognitive deficits of schizophrenia: 
verbal memory, recognition memory, attention, executive function, social cognition, 
reasoning, and problem solving (Green, 2006).
Current antipsychotic drugs have, at best, modest effects on cognitive deficits of 
schizophrenia in the vast majority of schizophrenia subjects (Gold, 2004; Hagan and Jones, 
2005). There is strong evidence that atypical antipsychotics generally produce an incomplete 
amelioration of cognitive deficits of schizophrenia, whereas there is controversy regarding 
whether typical antipsychotics produce an improvement in cognitive deficits of 
schizophrenia that is comparable to atypical antipsychotics or inferior to them (Green et al, 
2002; Harvey et al, 2005; Keefe et al, 2006; Mishara and Goldberg, 2004; Remillard et al, 
2005; Rollnik et al, 2002; Medalia et al, 1988; Stip et al, 2005; Lublin et al, 2005).
Increasing efforts are focused on developing drugs with robust benefits for cognitive deficits 
of schizophrenia. However, several limitations hamper this effort, including a relative dearth 
of well-established and validated animal models for these deficits. No single preclinical test 
is likely to model all domains of cognitive deficits of schizophrenia. Since the 
pathophysiology of cognitive deficits of schizophrenia, like non-cognitive deficits of 
schizophrenia features of schizophrenia, is not well understood, developing animal models 
of cognitive deficits of schizophrenia with etiological validity is challenging. Establishing 
predictive validity for cognitive deficits of schizophrenia presents another vexing problem 
since there are no established treatments with complete efficacy.
Pragmatic issues represent still another limitation to the development of new treatments for 
cognitive deficits of schizophrenia. Most preclinical cognitive tests are labor intensive, 
requiring training animals on a task for several consecutive days and thus hampering the 
ability to conduct high-throughput drug screening.
Paradigms examining novelty recognition in animals have been proposed as a valuable 
preclinical model of cognitive deficits that are seen in schizophrenia (Hagan and Jones, 
2005). Social recognition and social discrimination are two related examples of preclinical 
paradigms that assess socially based novelty discrimination and do not require pre-test 
training of animals (Engelmann et al, 1995).
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Investigators have previously focused on pharmacological approaches to induce, in animals, 
cognitive deficits seen in schizophrenia. For example, Terranova et al demonstrated that 
acute administration of the psychotomimetics PCP and D-amphetamine disrupted social 
discrimination in Wistar rats (Terranova et al, 2005). In addition, they found that subchronic 
administration of PCP during the neonatal period produced spontaneous deficits in social 
discrimination in adult rats. These deficits were reversed by the atypical antipsychotics 
clozapine and amisulpride, the putative atypical antipsychotic SSR181507 (Terranova et al, 
2005). These findings suggest that drug-induced disruption of social discrimination may be a 
useful animal model of cognitive deficits of schizophrenia with predictive utility for 
potential pro-cognitive drugs. However, in regards to developing animal models with 
optimal utility for drug discovery, pharmacologically-induced social discrimination deficits 
have the potential to introduce added experimental complexity, data variability, as well as 
potentially limiting drug discovery to agents, which specifically block the effects of the 
deficit-inducing drug (Floresco et al, 2005). An animal model based on innate social 
discrimination deficits could therefore provide a complementary alternative approach to 
those that required experimental manipulation.
Brattleboro (BRAT) rats are Long Evans (LE)-derived rats with a single-gene mutation that 
disrupts vasopressin secretion (Birkett and Pickering, 1988). BRAT rats homozygous for the 
mutation display a number of behaviors that are characteristic of those seen in schizophrenia 
patients, including abnormalities in memory (Laycock et al, 1983), stress reactivity 
(Williams et al, 1985), social recognition (Engelmann and Landgraf, 1994), and motivation 
(Williams et al, 1983) and attention (Williams et al, 1983) (but see, Jentsch et al, 2003). We 
have shown that BRAT rats exhibit natural schizophrenia-like deficits in prepulse inhibition 
of startle (PPI), a measure of sensorimotor gating processes. Furthermore, these PPI deficits 
are reversed by antipsychotics but not non-antipsychotic psychotropics. These findings 
suggest that the BRAT rat may be a good genetic animal model with predictive validity for 
antipsychotic drug efficacy. BRAT rats have been shown to exhibit social recognition 
deficits (Engelmann and Landgraf, 1994). Preliminary exploratory studies from our 
laboratory revealed that BRAT rats also appeared to exhibit deficits compared to LE rats in 
social discrimination.
The current study had several goals. First, we sought to confirm that BRAT rats exhibit 
natural social discrimination deficits. We also sought to begin to investigate the response of 
social discrimination deficits in BRAT to antipsychotics and putative antipsychotics that 
have been associated with pro-cognitive effects. In that regard, we tested the effects of the 
atypical antipsychotic clozapine on social discrimination in BRAT and LE rats, since 
clozapine has been shown to improve learning and delayed recall in schizophrenia patients 
(Woodward et al, 2005), two cognitive features required for social discrimination. 
Furthermore, clozapine reverses the PPI deficits in BRAT rats (Feifel et al, 2004; 2007) and 
scopolamine-induced social discrimination deficits in rats (Terranova et al, 2005). We also 
tested PD149163, which is a brain-penetrating agonist of the neurotensin-1 receptor. 
PD149163 is a putative antipsychotic drug, reversing PPI deficits in BRAT rats (Feifel et al, 
2004; Feifel et al, 2007) and demonstrating pro-cognitive effects in novel object recognition, 
a preclinical test similar to social discrimination (Azmi et al, 2006).
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METHODS
Animals
Experimental procedures were conducted in accordance with the University of California, 
San Diego guidelines for animal care and experimentation. All animals were purchased from 
Harlan Laboratories, San Diego, CA. Ninety-eight adult male BRAT rats and sixty-eight 
adult male LE rats (170–350 gms at testing) were housed in groups of two or three in clear 
plastic chambers in a climate controlled room under a 12/12 h light/dark schedule (lights 
on/off – 0700/1900). Male Sprague Dawley juvenile rats (25 – 30 days old) were used as 
social stimuli. All rats were allowed free access to food and water for the extent of the study. 
Behavioral testing was performed no earlier than 7 days after animals' arrival from the 
breeder. Each adult and each juvenile rat was used only one time.
Behavioral Procedure
The social discrimination procedure was modified from the social recognition test described 
by Engelmann et al, 1995. The social discrimination apparatus is made of a large plastic tub 
(30″ × 17″ × 12″) consisting of two small wire cages (6.5″ × 5″ × 4″) on either ends of the 
large tub in which the juvenile rats were placed. The purpose of the small wire cages was to 
restrict mobility of juvenile rats while allowing the adult rat visual, olfactory, and tactile 
access to the juveniles. This eliminated social contact that was initiated by the juveniles 
toward the adult. It also prevented simultaneous contact of the adult rat with both juveniles 
as well as juvenile-juvenile interaction, simplifying social interaction scoring. Each test trial 
included one adult rat, one familiar, previously exposed juvenile (familiar juvenile), and one 
novel juvenile. The social discrimination paradigm is illustrated in Figure 1. Briefly, adult 
rats acclimate in the social discrimination box for 20 minutes. Following this acclimation 
period, the learning trial begins with the adult rat exposed to a juvenile rat in one of the two 
small wire cages, randomly selected, for 4 minutes. The adult rat is then returned to its home 
cage for 30 minutes. During the test trial the adult animal is returned to the social 
discrimination box. Then the familiar juvenile, along with a novel juvenile, are placed in the 
two wire cages. In half the trials, the familiar juvenile returns to the same wire cage that the 
animal was initially placed in during the learning trial. In the other half of the trials, the rat is 
placed in the alternate wire cage. The adult rat is allotted four minutes to explore the 
juveniles. All sessions in the social discrimination box are videotaped and the tapes are 
scored by two raters blinded to the drug treatment and the strain of the rats. Each rater 
recorded the time each adult rat spent exploring the juvenile during learning trial, and the 
time the animal spent with the familiar and unfamiliar juvenile during the subsequent test 
trial.
Drug Treatment
Ten minutes prior to the acclimation period, animals were injected subcutaneously with 
either saline, clozapine (0.1 mg/kg, 1 mg/kg, 10 mg/kg) or PD149163 (0.1 mg/kg, 0.3 mg/kg 
or1.0 mg/kg). Social discrimination was then evaluated as described above. These doses 
selected for clozapine and PD149163 were based on the dose range found to be effective in 
reversing PPI deficits occurring naturally in BRAT rats and induced by psychotomimetics 
(Feifel et al, 2004; Feifel et al, 2007; Feifel et al, 1999; Feifel et al, 2003). Clozapine was 
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obtained from Sigma Chemicals, St. Louis, MO and PD149163 was provided courtesy of 
NIMH Chemical Synthesis and Drug Supply program, and SRI International, Menlo Park, 
CA. Clozapine was dissolved in half volume HCl and half volume 0.9% saline then titrated 
with NaOH to PH 7.0 . PD149163 was dissolved in 0.9% saline. Drugs were administered 
subcutaneously at a concentration of 1 ml/kg.
Statistical Analysis
Prior to analysis, data from animals that did not display any interaction (zero seconds) with a 
juvenile in either the learning or test periods were not included in the analysis, since animals 
that did not investigate the juvenile during the learning phase (zero seconds) could not be 
used to generate data on the test trial that could legitimately be considered a reflection of 
their retention of previous exposure to the juvenile. Similarly, any rat that displayed zero 
investigation of both novel and familiar juveniles during testing displayed non-investigatory 
behavior that cannot be considered a valid test of social memory. Ten LE and nineteen 
BRAT rats given PD149163 and two LE and ten BRAT rats given clozapine were, therefore, 
eliminated as was one BRAT rat given saline.
A Discrimination Index was calculated to determine preference of adult rats for exploration 
of the novel juvenile relative to the familiar juvenile in the test session. This index was 
calculated for each adult rat as percentage increase above the time each it spent exploring 
the familiar juvenile using the following formula: [(time exploring novel juvenile - time 
exploring familiar juvenile) / (time spend exploring familiar juvenile + time spent exploring 
novel juvenile)] (Grayson et al, 2007; Southam et al, 2008). Data were analyzed using the 
SPSS Explore function and extreme outliers (> 3 standard deviations from the mean 
excluded from the analysis). One LE rat in the high dose clozapine group and one LE rat in 
high dose PD149163 group were considered outliers using this analysis.
To determine whether each strain exhibited social discrimination under baseline (saline) 
conditions, absolute time spent with familiar juvenile and novel juvenile were compared 
using separate paired samples t-test for saline-treated LE and BRAT rats.
For LE rats, Discrimination Index, time exploring juvenile in the learning phase, time spent 
exploring familiar juvenile during test phase, and time spent exploring the novel juvenile 
during the test phase were each subjected to separate one-way ANOVAs with Drug 
Treatment as a between subject factor having seven elements (saline, clozapine × 3 doses, 
PD149163 × 3 doses). Drug effects for BRAT rats were assessed separately using an 
identical approach. Significant effects were followed up with pair-wise post-hoc 
comparisons using Fishers LSD. Alpha was set at 0.05.
RESULTS
Baseline Social Discrimination
As shown in Table 1, saline-treated LE rats spent significantly more time with the novel 
juvenile compared to familiar juvenile (t(23)=−2.80, P=0.01), whereas there was no 
significant difference between the time spent with novel and familiar juveniles among 
saline-treated BRAT rats (Table 2). There was no significant difference between LE and 
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BRAT rats in the average time each strain spent exploring the juvenile rats during the 
learning period.
Effect of Clozapine and PD149163 on Social Discrimination
As shown in Table 1, analysis of the LE data from the learning exposure period revealed that 
there was a general tendency for clozapine and PD149163 to reduce the time spent 
interacting with the juvenile during the learning exposure period although the main effect of 
drug treatment was not significant. Post hoc pair-wise comparison indicated that the 
interaction time exhibited by saline-treated LE rats during the learning period was 
significantly higher than the interaction time exhibited by LE rats treated with the highest 
dose of clozapine (P<0.05) and PD149163 (P<0.05). Analysis of Discrimination Index data 
revealed no significant main effect of Drug Treatment in the LE rats (Figure 2). Planned 
post-hoc comparisons revealed that the 0.3 mg/kg dose of PD149163 significantly increased 
the Discrimination Index relative to saline in LE rats (P<0.05). There was no significant 
effect of either drug on the time LE rats spent interacting with the novel juvenile compared 
to saline. Similarly, there was no significant effect of either drug on the time LE rats spent 
interacting with the familiar juvenile compared to saline.
In BRAT rats, clozapine and PD149163 produced a more pronounced reduction in 
exploration of the juvenile during the learning period (Table 2) and this was revealed as a 
significant main effect of Drug Treatment (F6,97=5.48, P<0.001) in this strain. Post-hoc pair-
wise comparisons revealed that BRAT rats treated with saline have significantly higher 
interaction times with the juvenile during the learning period compared with BRAT rats 
treated with all three doses of clozapine (P=0.047, P=0.023, P=0.013, respectively) and all 
three doses of PD149163 tested (P=0.002, P<0.001, and P<0.001, respectively).
Figure 3 illustrates the effects of clozapine and PD149163 on social discrimination in BRAT 
rats. Analysis of Discrimination Index data revealed there was a significant main effect of 
drug treatment (F6,97=5.79, P<0.001). Post hoc comparison revealed that the highest dose of 
clozapine, 10 mg/kg (P<0.001) and the two highest doses of PD149163, 0.3 mg/kg 
(P<0.001) and 1.0 mg/kg (P=0.02) significantly increased the Discrimination Index 
compared to saline in BRAT rats.
Both clozapine and PD149163 decreased the time BRAT rats spent interacting with the 
familiar juvenile during the test period (Table 2), revealed as a main effect of drug treatment 
(F6,104=4.68, P < 0.001). Post-hoc comparisons showed that the middle and high doses of 
clozapine (1.0 mg/kg: P<0.001, 10.0 mg/kg: P<0.001) and PD149163 (0.3 mg/kg: P<0.001, 
1.0mg/kg: P=0.006) produced a significant reduction in interaction with the familiar 
juvenile. There was no significant effect of either drug on the time BRAT rats spend 
interacting with the novel juvenile compared to saline.
As seen in Table 1, neither clozapine nor PD149163 had a significant effect on the time LE 
rats spent with the novel juvenile during the test period. However in BRAT rats, clozapine 
and PD149163 tended to produce different effects, neither of which achieved significance. 
Clozapine tended to decrease, whereas PD149163 tended to increase time spent interacting 
with the novel juvenile.
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DISCUSSION
The findings in this report confirm that BRAT rats exhibit natural social discrimination 
impairment since saline-treated BRAT rats spent comparable amount of time interacting 
with the novel and familiar juvenile rats. In contrast, saline-treated LE had intact social 
discrimination as they spent significantly greater time interacting with the novel juvenile. 
The social discrimination deficits observed in BRAT rats are consistent with previous 
studies showing that this strain does not exhibit intact social memory in a social recognition 
paradigm (Engelmann and Landgraf, 1994). Moreover, the social discrimination deficit 
exhibited by BRAT rats seemed to be a true deficit in social memory rather than a non-
specific reduction in social motivation or general activity, since saline-treated BRAT and LE 
rats displayed comparable time exploring the juvenile rat during the learning period.
The BRAT rat, to the best of our knowledge, is the only rat strain to display natural social 
discrimination deficits. Vasopressin receptor and oxytocin receptor null mice have also been 
shown to exhibit natural deficits in social memory (Bielsky et al, 2004;Wersinger et al, 
2004; Winslow and Insel, 2002). Oxytocin and vasopressin are chemically and functionally 
related neurohormones that have both been implicated in the regulation of social behavior.
Prior to this study, BRAT rats were already known to display several features analogous to 
schizophrenia, including deficits in memory (Laycock et al, 1983), response to stress 
(Williams et al, 1985), motivation and attention (Williams et al, 1983), startle habituation 
and prepulse inhibition (Feifel and Priebe, 2001), as well as elevated levels of striatal D2 
binding (Shilling et al, 2006). The current demonstration of natural social discrimination 
deficits in BRAT rats adds to the schizophrenia-relevant phenotypic profile these animals 
display.
In this study, the atypical antipsychotic clozapine produced a dose-dependent enhancement 
of social discrimination in the BRAT rats. Clozapine has been shown to reverse PCP-
induced, novel object recognition deficits, an animal test that is very similar to social 
discrimination (Grayson et al, 2007) and the current results are consistent with results such 
as this from related preclinical tests. In regards to clozapine's effects on cognitive deficits in 
humans, a meta-analysis of treatment studies of schizophrenia patients revealed that, overall, 
clozapine enhances cognitive performance in schizophrenia patients and specifically two 
cognitive domains relevant to social discrimination: learning and delayed recall (Woodward 
et al, 2005). Therefore, it is reasonable to interpret the improvement in BRAT rat social 
discrimination seen with clozapine as consistent with the clinical experience with clozapine, 
and thus providing preliminary predictive validity for the BRAT rat model of cognitive 
deficits. Tests of other antipsychotics will be needed in order to more conclusively establish 
this contention. However, establishing predictive validity for cognitive deficits of 
schizophrenia is not a straightforward matter since the benefits of antipsychotics are modest 
and somewhat controversial. For example, while it is generally accepted that atypical 
antipsychotics such as clozapine improve cognitive deficits of schizophrenia, there is 
conflicting evidence regarding whether typical antipsychotics such as haloperidol produce 
improvements in cognitive deficits of schizophrenia (Green et al, 2002; Harvey et al, 2005; 
Keefe et al, 2006; Mishara and Goldberg, 2004; Remillard et al, 2005; Rollnik et al, 2002; 
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Medalia et al, 1988; Stip et al, 2005; Lublin et al, 2005). Haloperidol is not effective in 
some animal models of cognitive deficits of schizophrenia, namely those based on PCP-
induced deficits, whereas it does ameliorate the deficits in other preclinical cognitive deficits 
of schizophrenia models (e.g. Becker & Grecksch, 2006; Dunn and Kilcross, 2006; 
Besbalov et al, 2007). Thus, it would be harder to interpret the haloperidol findings in 
regards to their implications for predictive validity and for that reason we chose to test 
clozapine in this initial study of cognitive deficits in BRAT rats.
In contrast to its effects in BRAT rats, clozapine did not improve social discrimination in LE 
rats. In fact, it had the opposite effect, negating the natural social discrimination seen in 
saline-treated LE rats (Table 1). Therefore, the results suggest that the beneficial effects of 
clozapine on social discrimination were specific to the BRAT rats. This specificity is 
another aspect that supports validity for cognitive deficits of schizophrenia, since 
antipsychotics such as clozapine are not considered to be general cognitive enhancers in 
normal humans or patients that do not have psychotic disorders, and is considered a 
cognitive impairing drug in humans that do not suffer from schizophrenia or other related 
psychotic disorders due to its propensity to produce anticholinergic and sedating effects.
PD149163 is an analog of neurotensin, a thirteen amino acid gut-brain peptide. Neurotensin 
has been proposed to be an endogenous antipsychotic due to, among other things, its ability 
to inhibit mesolimbic dopamine function (Kinkead and Nemeroff, 2006). While neurotensin 
does not enter the brain after systemic administration, PD149163 was designed to do so. 
This compound was developed by chemically modifying the c-terminal hexapeptide 
fragment, neurotensin(8-13), the smallest fragment that retains the full bioactivity of 
neurotensin, to make it more resistant to enzymatic degradation (Banks et al, 1995). In 
previous preclinical studies with PD149163 we found that it produced robust antipsychotic-
like effects more similar to atypical than typical antipsychotics. In BRAT rats, a single 
administration of PD149163 was able to reverse their PPI deficits, as did clozapine but not 
haloperidol (Feifel et al, 2004). This effect persisted in BRAT rats after chronic 
administration of PD149163 (Feifel et al, 2007). Recently, Azmi et al, (2006) found that 
PD149163 administered to rats restored novel object recognition impaired by the 
anticholingergic scopolamine (Azmi et al, 2006) and that same group also reported that 
PD149163 increased associative learning in a trace conditioning paradigm (Grimond-Billa et 
al, 2008). Consistent with those findings and with clozapine effects in this study, acute 
administration of PD149163 improved social discrimination in this study in BRAT rats, but 
unlike clozapine the most effective dose of PD149163 in BRAT rats (0.3 mg/kg) also 
improved social discrimination in LE rats.
The social discrimination test is based upon the social recognition test in which only the 
familiar juvenile is re-introduced during the testing session and reduction in time spent 
investigating that juvenile is evidence of intact social memory (Engelmann et al, 1994). The 
introduction of a second, novel juvenile in the discrimination test was used primarily to 
control for non-specific reductions in investigation, e.g. sedation, that might affect the 
second exposure. The improvement in Discrimination Index scores by clozapine and 
PD149163 in this study was due specifically to decrease in the time investigating the 
familiar juveniles, whereas investigation time of the new juveniles was not altered. Thus, the 
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effect produced by clozapine and PD149163 of reduced exploration of the familiar juvenile 
is the classical operational measure of social memory (Engelmann et al, 1994).
The exact mechanisms underlying PD149163's pro-cognitive effects in this and previous 
studies are not known. PD149163 is selective for the NT1 receptor (Petrie et al., 2004), the 
neurotensin receptor subtype most implicated in neurotensin's antipsychotic-like effect. 
Azmi et al speculate the NT1-mediated enhancement of muscarinic transmission may be 
involved. PD149163 has also been shown to increase neuronal activation in the prefrontal 
cortex (Azmi et al, 2006) and this activation may contribute to its cognitive effects (Petrie et 
al, 2004). In any case, these results enhance the candidacy of NT1 agonists as potentially 
novel antipsychotics that may have benefit for cognitive deficits of schizophrenia. It is 
interesting that the dose of PD149163 that was most effective in increasing social 
discrimination in BRAT rats (0.3 mg/kg) also improved social discrimination LE rats. This 
suggests that PD149163 may facilitate non-impaired memory.
It is noteworthy that both clozapine and PD149163 enhanced social discrimination in test 
trials despite that both drugs reduced exploration time of LE and BRAT rats during the 
learning period. This reduction in exploration during the learning period is likely due to a 
non-specific inhibitory effect on activity since both drugs are known to decrease 
spontaneous locomotor activity (Wiley, 2008; Norman et al. 2008). Thus, it appears that the 
reduction in exploratory contact during the learning period produced by clozapine and 
PD149163 was more than compensated for by enhanced information acquisition during this 
period in BRAT rats but not LE rats; in essence, clozapine produced more efficient learning 
in BRAT rats (more retention despite less opportunity to learn). This seemingly paradoxical 
effect has been reported with PD149163 and atypical antipsychotics in the novel object 
recognition test which is similar to social discrimination (Azmi et al, 2006; Nagai et al, 
2008). Indeed, among rats treated with clozapine and PD149163, there was a inverse 
relationship between time spent interacting with the juvenile during the learning phase and 
their subsequent social discrimination performance (Pearson r = −0.182, p=0.06); the more a 
rat's learning period interaction was suppressed, the better they performed subsequently on 
social discrimination. Therefore, the mechanism underlying the reduction of spontaneous 
locomotion produced by these drugs may also be involved in the enhanced cognitive 
performance. Some rats treated with higher doses of clozapine and PD149163 had to be 
eliminated from the data analysis altogether, since they displayed a profound reduction in 
spontaneous locomotion and no interaction at all (zero seconds) with the juvenile during the 
learning period. It is unlikely that this selective elimination of rats contributed to the positive 
finding on the social discrimation performance that we observed due to the inverse 
relationship noted above between interaction suppression and enhancement of social 
discrimination.
In this study clozapine and PD149163 improved social discrimination after a single 
administration. This is consistent with most other preclinical tests of antipsychotics and 
other cognitive enhancing treatments where significant effects are seen following a single 
dose. It is commonly believed that improvement of cognitive deficits of schizophrenia 
occurs only with chronic use of antipsychotics and not after a single dose. However, a 
similar common assumption about the time course of antipsychotic drug benefits on the core 
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symptoms of schizophrenia has recently been proven inaccurate by recent meta-analyses of 
clinical data that reveal significant benefits begin after a single dose of antipsychotics but 
require chronic use to achieve optimal effects (Agid et al, 2006; Agid et al, 2008). It is 
possible therefore that the same holds true for improvement in cognitive deficits of 
schizophrenia by antipsychotics, but the time course of antipsychotic-induced cognitive 
deficits of schizophrenia improvements has not been studied. In this regard, we have shown 
that the natural PPI deficits in BRAT rats are enhanced by a single administration of atypical 
antipsychotics and this effect increases with chronic administration (Feifel et al, 2007). 
Future studies should investigate the relative effects of acute and chronic clozapine, 
PD149163 and other antipsychotics on social discrimination deficits in BRAT rats.
Social discrimination abnormalities in BRAT rats, like the PPI deficits exhibited by this rat 
strain, may serve as a genetic animal model of schizophrenia cognitive deficits. Further 
study of this model may aid in elucidating novel genes or pathways implicated in the 
neuropathology of the disorder. In addition, the results of this study serve as preliminary 
evidence that the social discrimination deficits in BRAT rats may serve as a predictive 
model of novel antipsychotic efficacy in cognitive domains.
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Figure 1. 
Illustration of the Social Discrimination Paradigm. Adult rats acclimate in the social 
discrimination box for 20 minutes. Following this acclimation period, the learning trial 
begins with the adult rat exposed to a juvenile rat for 4 minutes. The adult rat is then 
returned to its home cage for 30 minutes. During the retrieval trial the adult animal returns to 
the chamber with the introduction of a new juvenile along with the same juvenile from the 
learning trial for 4 minutes. The positions of the juveniles are randomly alternated
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Figure 2. 
The effects of saline (n=20), PD149163 and clozapine (n = 7-8 per dose) on the 
Discrimination Index in LE rats. Discrimination Index equals (time spent investigating new 
juvenile - time spent investigating familiar juvenile) / (time spent investigating new juvenile 
+ time spent investigating familiar juvenile). Significantly higher than saline is represented 
by * (P< 0.05).
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Figure 3. 
The effects of saline (n = 36), PD149163 and clozapine (n = 11-15 per dose) on the 
Discrimination Index in BRAT rats. Discrimination Index equals (time spent investigating 
new juvenile - time spent investigating familiar juvenile) / (time spent investigating new 
juvenile + time spent investigating familiar juvenile). Significantly higher than saline is 
represented by * (P< 0.05) and ** (P< 0.01).
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